CA2359469A1 - Compositions et methodes de traitement et de prevention d'infections bacteriennes pathogenes basees sur le role essentiel de la methylation de l'adn dans la virulence bacterienne - Google Patents

Compositions et methodes de traitement et de prevention d'infections bacteriennes pathogenes basees sur le role essentiel de la methylation de l'adn dans la virulence bacterienne Download PDF

Info

Publication number
CA2359469A1
CA2359469A1 CA002359469A CA2359469A CA2359469A1 CA 2359469 A1 CA2359469 A1 CA 2359469A1 CA 002359469 A CA002359469 A CA 002359469A CA 2359469 A CA2359469 A CA 2359469A CA 2359469 A1 CA2359469 A1 CA 2359469A1
Authority
CA
Canada
Prior art keywords
dam
immunogenic composition
mutation
salmonella
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002359469A
Other languages
English (en)
Inventor
Michael J. Mahan
Douglas M. Heithoff
David A. Low
Robert L. Sinsheimer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2359469A1 publication Critical patent/CA2359469A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions de vaccins contenant des bactéries pathogènes, telles que la Salmonellose, subissant des mutations génétiques sans réversion qui altèrent l'activité de la méthylase d'adénine de l'ADN (Dam), et des méthodes dans lesquelles ces compositions sont utilisées afin de produire une réponse immunitaire. L'invention concerne également des méthodes de préparation de vaccins ainsi que des méthodes de recherche visant à identifier des agents pouvant avoir une activité antibactérienne.
CA002359469A 1999-02-02 2000-02-02 Compositions et methodes de traitement et de prevention d'infections bacteriennes pathogenes basees sur le role essentiel de la methylation de l'adn dans la virulence bacterienne Abandoned CA2359469A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24195199A 1999-02-02 1999-02-02
US09/241,951 1999-02-02
US30560399A 1999-05-05 1999-05-05
US09/305,603 1999-05-05
US49561400A 2000-02-01 2000-02-01
US09/495,614 2000-02-01
PCT/US2000/002866 WO2000045840A1 (fr) 1999-02-02 2000-02-02 Compositions et methodes de traitement et de prevention d'infections bacteriennes pathogenes basees sur le role essentiel de la methylation de l'adn dans la virulence bacterienne

Publications (1)

Publication Number Publication Date
CA2359469A1 true CA2359469A1 (fr) 2000-08-10

Family

ID=27399537

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002359469A Abandoned CA2359469A1 (fr) 1999-02-02 2000-02-02 Compositions et methodes de traitement et de prevention d'infections bacteriennes pathogenes basees sur le role essentiel de la methylation de l'adn dans la virulence bacterienne

Country Status (8)

Country Link
EP (1) EP1150711A1 (fr)
JP (1) JP2002536339A (fr)
AU (1) AU776864B2 (fr)
BR (1) BR0007966A (fr)
CA (1) CA2359469A1 (fr)
MX (1) MXPA01007747A (fr)
NZ (1) NZ512685A (fr)
WO (1) WO2000045840A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US6602680B2 (en) 2000-07-14 2003-08-05 The Regents Of The University Of California Production of gabaergic cells
GB0029379D0 (en) * 2000-12-01 2001-01-17 Arrow Therapeutics Ltd A method for identifying enzyme inhibitors
ITRM20010295A1 (it) * 2001-05-30 2002-12-02 Stresstech S R L Metodo per ottenere microrganismi patogeni non virulenti attraverso una modificazione dello stato fisico e/o dinamico delle loro membrane bi
JP2003189861A (ja) * 2001-12-25 2003-07-08 Japan Science & Technology Corp 細菌の運動性関連遺伝子群発現の制御
JP2022543668A (ja) 2019-08-09 2022-10-13 ナットクラッカー セラピューティクス， インコーポレイテッド マイクロ流体装置およびその使用方法
WO2021107013A1 (fr) * 2019-11-29 2021-06-03 国立研究開発法人理化学研究所 Composition d'adjuvant

Also Published As

Publication number Publication date
EP1150711A1 (fr) 2001-11-07
WO2000045840A1 (fr) 2000-08-10
JP2002536339A (ja) 2002-10-29
BR0007966A (pt) 2001-11-06
AU3222100A (en) 2000-08-25
AU776864B2 (en) 2004-09-23
WO2000045840A8 (fr) 2001-03-22
MXPA01007747A (es) 2002-07-02
NZ512685A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
US6399074B1 (en) Live attenuated salmonella vaccines to control avian pathogens
JP2640525B2 (ja) 無毒の微生物とその使用
JPS62501211A (ja) 新規な非復帰性サルモネラ生ワクチン
US20110052635A1 (en) Live attenuated salmonella vaccine
US9399057B2 (en) Salmonella vaccine
CN104797268B (zh) 一种新型志贺氏菌减毒活疫苗
Homchampa et al. Molecular analysis of the aroA gene of Pasteurella multocida and vaccine potential of a constructed aroA mutant
US6902906B1 (en) Bacteria attenuated by a non-reverting mutation in each of the aroC, ompF and ompC genes, useful as vaccines
AU783508B2 (en) Salmonella vaccine
US7026155B2 (en) Method of reducing bacterial proliferation
US20020068068A1 (en) Method of creating antibodies and compositions used for same
US20020076417A1 (en) Attenuated bacteria with altered DNA adenine methylase activity
AU776864B2 (en) Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence
US20020081317A1 (en) Bacteria with altered DNA adenine methylase (DAM) activity and heterologous epitope
US20020086032A1 (en) Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity
US20020077272A1 (en) Reducing bacterial virulence
JP2005519872A (ja) サルモネラ・ワクチン
JP2009529895A (ja) 弱毒化サルモネラ生ワクチン
US20220218810A1 (en) New immunogenic compositions
KR20010039651A (ko) 백신용 약독화 생박테리아
ZA200105305B (en) Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence.
Choi et al. Salmonella enterica serovar Typhimurium ruvB mutant can confer protection against salmonellosis in mice
EP1181371B1 (fr) Souches attenuees mutantes d'e. coli enteropathogene (epec), procede de production et utilisation
KR20080105099A (ko) 약독화 살모넬라 생백신
Guzman et al. Vaccines against Infections Caused by Salmonella, Shigella, and Pathogenic Escherichia coli

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead